The Impact of COVID-19 Infection and Vaccination on the Production of Anti-TPO Antibodies and Its Implications for Thyroid Disease Development

• by Arwa Qaqish, Mohammad Al-Tamimi, Manal Mohammad Abbas, Obada Al Jayyousi, Shahd Tarawneh, Abdel-Ellah Al-Shudifat, Rami Alqassieh, Moawiah Khatatbeh

• January 7, 2026

Extended antiviral therapy may not improve long COVID

Nirmatrelvir–ritonavir for up to 25 days failed to improve cognitive, autonomic, or exercise symptoms compared with placebo in a phase 2 trial.

• by Andrea Surnit

• September 4, 2026

• 4 min

Pneumonia Etiology and Risk Factors in a Tertiary Hospital During the COVID-19 Era: A Retrospective Analysis (2020–2024)

• by Nikolaus Clodi, Friedrich Berthold, Thomas Berger, Martin Clodi, Michael Resl

• July 13, 2026

The drugs and devices have been on the market for years. But FDA-ordered studies still aren’t done.

“Doctors rely on this evidence, patients rely on this evidence, and if that evidence is not there, it’s going to lead to a lot of uncertainty."

• by David Hilzenrath

• September 22, 2026

• 14 min